Alnylam Pharmaceuticals
ALNY
403 hedge funds and large institutions have $21B invested in Alnylam Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 154 increasing their positions, 122 reducing their positions, and 41 closing their positions.
98% more call options, than puts
Call options by funds: $275M | Put options by funds: $138M
26% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 122
17% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 41
10% more capital invested
Capital invested by funds: $19B → $21B (+$1.99B)
1% more funds holding
Funds holding: 400 → 403 (+3)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1.59% less ownership
Funds ownership: 95.54% → 93.95% (-1.6%)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$52.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$43.5M |
| 4 |
BlackRock
New York
|
+$42.1M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$36.7M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$339M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$54.2M |
| 3 |
Alkeon Capital Management
New York
|
-$50.3M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$28.1M |
| 5 |
JP Morgan Chase
New York
|
-$26.8M |
ALNY Hedge Fund Activity: Q3 2021 in Review
403 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2021, worth a combined $21B — up 10% from $19B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ALNY positions and 41 closed out — a net gain of 7 holders — while 154 added to existing stakes and 122 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $65.6M. The largest seller was Wellington Management Group, cutting an estimated $339M.
- 403 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2021, up from 400 in Q2 2021.
- Funds reported $21B of Alnylam Pharmaceuticals stock for Q3 2021, up 10% quarter-over-quarter.
- 48 funds opened new Alnylam Pharmaceuticals positions in Q3 2021 and 41 closed out, a net change of +7 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2021 was T. Rowe Price Associates, an estimated $65.6M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $339M sold.
Based on aggregated 13F filings for Q3 2021.